Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum CCFM1029
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum CCFM1029 is a specific probiotic strain of the species Bifidobacterium longum, belonging to the family Bifidobacteriaceae. It is used as a live biotherapeutic product and dietary supplement, primarily investigated for its ability to improve atopic dermatitis and balance immune responses. Mechanistically, it modulates tryptophan metabolism via the gut-skin axis, upregulating indole-3-carbinol (I3C) production to suppress aberrant T helper 2 (Th2) immune responses[1][4]. Clinical studies have shown that supplementation with this strain can improve Th1/Th2 immune balance, regulate intestinal flora and short-chain fatty acid metabolism, relieve inflammatory infiltration in skin tissue, and reduce cytokines IL-4 and IL-13 associated with Th2-type inflammation[1][5]. There is also evidence suggesting potential benefits in relieving symptoms of Parkinson's disease through modulation of gut microbiota and neuroinflammation[6]. The strain has been developed for use in capsules, tablets, stick-packs, foods (including dairy products), nutraceuticals, or pharmaceuticals.
- Other names
- B. longum CCFM1029
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on bifidobacterium longum CCFM1029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum CCFM1029.